BMT cost in Turkey

Bone marrow transplant cost in Turkey by donor, conditioning, and recovery risk

A credible HSCT estimate separates disease reassessment, donor typing and search, stem-cell collection, conditioning medicines, cell processing, protected-room admission, transfusions, infection treatment, engraftment monitoring, graft-versus-host disease care, and the required local follow-up period. Autologous and allogeneic transplant are not one product.

How much does bone marrow transplant cost in Turkey?

International-patient planning ranges in Turkey are commonly about TRY 940,000 to 1,410,000 (USD 20,000 to 30,000) for autologous HSCT and TRY 1,410,000 to 2,820,000 (USD 30,000 to 60,000) for matched, haploidentical, or unrelated-donor allogeneic HSCT. Donor procurement, severe infection, graft failure, intensive care, GVHD, or readmission can push the total higher.

Conversions use about TRY 47 per USD near the official 17 July 2026 indicative rate. Transplant quotations may use EUR or USD for imported medicines and donor services; confirm the controlling currency and validity period.

Review cost scenarios Upload reports

Let Us Help You

Share the basics and the Virello team will guide you toward the next step.

Prefer email? Write to support@virellohealth.com.

Patient Name

Country

Phone Number

Describe The Current Medical Problem

Reviewed 2026-07-19

Clinical review: Virello Health Clinical Content Team · Editorial review: Virello Health Research Team

Billing context: TRY and USD

Infusion is one day

The expensive and clinically demanding pathway includes preparation, conditioning, aplasia, engraftment, immune recovery, and months of surveillance.

Donor changes the budget

Related, haploidentical, unrelated, marrow, peripheral-blood, and cord pathways require different testing, collection, procurement, and prevention plans.

Quality system matters

Ask about the transplant program’s current authorization, cellular-therapy quality system, laboratory chain of identity, infection controls, and patient group.

Stay near the center

Allogeneic recipients often need prolonged local access after discharge for blood tests, transfusion, infection, GVHD, and medicine adjustment.

Cost at a glance

Planning scenarios for bone marrow transplant in Turkey

The scenarios separate routine and complex pathways. They are not fixed packages and should be replaced by a report-led hospital estimate before travel.

Estimated bone marrow transplant cost scenarios in Turkey
Scenario	TRY	USD	Patient and treatment context	Planning scope
Autologous HSCT	TRY 940,000 - 1,410,000	USD 20,000 - 30,000	Patient’s own cells collected after mobilization for selected lymphoma, myeloma, or other indications.	Should include mobilization assumptions, collection, cryopreservation, conditioning, infusion, protected admission, and early monitoring.
Related-donor allogeneic HSCT	TRY 1,410,000 - 2,115,000	USD 30,000 - 45,000	Matched sibling or selected haploidentical pathway with donor medically cleared and available.	Needs separate donor testing, collection, conditioning, GVHD prevention, and both patient and donor scope.
Unrelated donor or complex course	TRY 2,115,000 - 2,820,000+	USD 45,000 - 60,000+	Registry search and procurement, mismatched donor, intensive conditioning, active infection, prior transplant, or high readmission risk.	External donor fees and major complication treatment must be itemized.

Usually included

Check the clinical package scope

Pre-transplant evaluation

Disease status, organ function, infection screening, dental and psychosocial review.

Define included repeat testing.

Cell pathway

Mobilization, collection, processing, storage, release, and infusion as specified.

Unrelated registry procurement may be separate.

Conditioning and protected stay

Named regimen or allowance, isolation room, routine transfusion and monitoring limits.

Get daily overstay and medicine caps.

Early transplant follow-up

Scheduled laboratory, chimerism or disease checks, medicine adjustment, and line care.

State the included post-discharge days.

Confirm separately

Charges that may sit outside the range

Donor search and procurement

Registry activation, confirmatory typing, collection, courier, and international fees.

Obtain a donor-stage budget.

High-cost infection treatment

Advanced antimicrobials, viral therapy, ICU, ventilation, or prolonged isolation.

Ask about medicine limits.

GVHD or graft failure

Biopsy, immunosuppression, extracorporeal therapy, second collection, boost, or repeat transplant.

These are major additional pathways.

Living and long-term care

Apartment, caregiver, food precautions, transport, vaccines, home hematology, and readmission.

Model several months, not only admission.

Candidate context

Who may be considered and what else may be discussed

HSCT suitability depends on the exact disease, molecular and remission status, previous treatment, donor options, age, organ reserve, performance status, infection history, psychosocial support, and whether transplant offers a favorable balance against non-transplant therapy. Urgent leukemia or severe infection management should not be delayed for destination shopping. A transplant hematologist must review original pathology and treatment response.

Information that shapes suitability

Disease indication and timing

Diagnosis, risk markers, remission depth, prior lines, refractory disease, and urgency determine whether and when transplant is useful.

Donor and graft

HLA match, donor age and health, antibodies, cell source, collection logistics, and backup donor affect plan.

Organ and infection reserve

Heart, lung, kidney, liver, nutrition, dental status, latent infection, and current cultures shape conditioning risk.

Caregiver and continuity

A reliable caregiver, safe accommodation, rapid hospital access, medicine supply, and home hematologist are essential.

Alternatives or sequencing questions

Non-transplant systemic therapy

Targeted therapy, immunotherapy, chemotherapy, or maintenance may be preferred by disease and response.

Cellular therapy or clinical trial

Selected diseases may have CAR-T or investigational options with different timing and risks.

Delay for disease or infection control

Additional treatment may be needed to reach safer disease status or control infection before conditioning.

Procedure variations

Why the named procedure does not have one price

Technique, device, medicine, treatment extent, and prior care can change both the clinical plan and the estimate.

Autologous transplant

Uses the patient’s collected cells and has no donor GVHD.

Mobilization failure can change the plan.

Matched sibling allogeneic

Uses a suitably matched related donor.

Both donor and recipient need independent assessment.

Haploidentical transplant

Uses a partially matched related donor with specialized GVHD prevention.

Compare center-specific experience.

Unrelated donor transplant

Requires registry search, confirmation, collection, transport, and timing coordination.

Procurement can be a large separate cost.

City comparison

Cost and capability by city in Turkey

Only cities with evidence for the procedure should appear here. A city range does not prove that every hospital in that city can manage the same case complexity.

Estimated bone marrow transplant costs and planning context by city in Turkey
City	Local range	USD range	Capability context	Stay planning
Istanbul	TRY 1,081,000 - 2,820,000	USD 23,000 - 60,000	Broad adult and pediatric tertiary choice.	Budget long accommodation.
Ankara	TRY 1,034,000 - 2,585,000	USD 22,000 - 55,000	Major academic hematology programs.	Confirm international patient access.
Izmir	TRY 987,000 - 2,350,000	USD 21,000 - 50,000	Established transplant programs including pediatric capability.	Verify current age group and accreditation scope.
Antalya	TRY 1,034,000 - 2,444,000	USD 22,000 - 52,000	Selected private international pathways.	Confirm protected-unit depth.
Bursa	TRY 940,000 - 2,256,000	USD 20,000 - 48,000	Selected tertiary availability.	Validate disease and donor capability.
Kocaeli and Gebze	TRY 1,034,000 - 2,585,000	USD 22,000 - 55,000	Marmara transplant options.	Plan caregiver transport.
Adana	TRY 940,000 - 2,350,000	USD 20,000 - 50,000	Selected academic BMT services.	Check current international intake.
Kayseri	TRY 940,000 - 2,350,000	USD 20,000 - 50,000	Current JACIE activity has included pediatric programs.	Verify adult versus pediatric scope.
Konya	TRY 893,000 - 2,115,000	USD 19,000 - 45,000	Case-specific tertiary availability.	Do not infer capability from city alone.
Gaziantep	TRY 893,000 - 2,115,000	USD 19,000 - 45,000	Requires program-level validation.	Confirm cellular laboratory and ICU.

Estimate variables

What can change the final hospital cost

Transplant and donor type

Autologous, related, haploidentical, unrelated, and graft source determine major components.

Price donor separately.

Conditioning and medicines

Intensity, drug selection, GVHD prevention, and antimicrobials alter cost.

Use named regimen assumptions.

Aplasia and complications

Engraftment delay, infection, organ injury, GVHD, and ICU use extend care.

Keep a large reserve.

Local follow-up duration

Frequent tests, transfusion, line care, lodging, and caregiver needs continue after discharge.

Include the whole local period.

Medical cost breakdown

Before admission, in hospital, and after discharge

Diagnostics and preparation

Disease confirmation

Pathology review, marrow, flow, molecular, cytogenetic, and imaging tests.

Resolve discordant diagnoses.

Recipient fitness

Heart, lung, kidney, liver, infection, dental, nutrition, and psychosocial assessment.

Conditioning depends on reserve.

Donor evaluation

HLA confirmation, health, infection, compatibility, and collection planning.

Keep donor consent independent.

Admission and treatment

Conditioning and cells

Regimen, collection or procurement, processing, storage, and infusion.

Define drug and cell-source scope.

Protected admission

Isolation, transfusion, laboratory monitoring, line care, nutrition, and routine prevention.

State day and unit limits.

Complication treatment

Antimicrobials, ICU, dialysis, GVHD therapy, or additional cellular product.

Usually variable.

Recovery and follow-up

Frequent outpatient monitoring

Counts, chemistry, drug levels, infection tests, chimerism, and disease assessment.

Schedule and price the first 100 days.

Medicines and transfusion

Immunosuppression, prevention, blood support, and line supplies.

Access can change quickly.

Vaccination and late effects

Revaccination, endocrine, fertility, bone, lung, eye, and malignancy surveillance.

Handover for years.

Complete journey budget

Plan beyond the hospital invoice

Patient and attendant costs should be modeled separately from the medical estimate, with flexible dates and a contingency reserve.

Long-stay accommodation

Low-risk housing near the unit for patient and caregiver.

Ask about kitchen and infection precautions.

Caregiver and transport

Dedicated support and rapid clinic access.

Public transit may be inappropriate during immunosuppression.

Readmission reserve

Unplanned admission, extra medicines, transfusion, and changed flights.

Do not rely on a narrow package.

Country access

Rules and practical requirements to verify

Visa, donor, fertility, medicine, licensing, and treatment-access requirements can change. Confirm current rules with the relevant authority and treating hospital.

Authorized hospital and program

Verify international-health-tourism authorization and the transplant program’s current patient age, disease, donor, and cellular-processing scope.

Independent donor safeguards

Donor consent, medical fitness, privacy, and absence of payment or pressure must be documented.

Visa and extended stay

Check official entry and extension requirements for patient, donor, and caregiver before conditioning.

Cell transport and records

If cells cross borders, confirm registry, courier, chain-of-identity, customs, contingency, and documentation.

Hospital selection

Compare capability before package price

Program identity

Adult or pediatric scope, transplant types, disease mix, current authorization, and quality accreditation.

Verify current status directly.

Cell laboratory

Collection, processing, cryopreservation, testing, release, traceability, backup power, and chain of identity.

Ask where each step occurs.

Infection and ICU depth

Protected rooms, microbiology, imaging, infectious disease, blood bank, dialysis, ventilation, and ICU.

Round-the-clock access is essential.

Outcome transparency

Day-100 and longer outcomes by disease, age, donor, and risk with defined denominators.

Reject one universal success rate.

Treating team

Specialists and support that may matter

Transplant hematologist

Confirms indication, donor strategy, conditioning, complications, and follow-up.

Cell collection and laboratory team

Manages apheresis or marrow collection, processing, storage, release, and traceability.

Infectious disease and critical care

Prevents and treats severe infection and organ complications.

Donor and survivorship services

Protects donor welfare and coordinates rehabilitation, fertility, vaccines, and late effects.

Treatment timeline

From report review to return-home follow-up

Disease and donor review

Confirm pathology, status, prior treatment, recipient reserve, HLA options, and budget before travel.

Arrival workup

Repeat critical testing, clear donor, control infection, finalize conditioning, and sign clinical and financial consent.

Collection and conditioning

Cells are secured and the patient receives the planned preparative regimen.

Infusion and engraftment

The team monitors counts, infection, organs, transfusion, GVHD, nutrition, and line.

Local early follow-up

Frequent outpatient care continues until the team considers remote continuity sufficiently safe.

Home survivorship

Hematology receives disease, donor, cell, medicine, vaccine, infection, and emergency records.

Risks and edge cases

Events that can change the plan, stay, or cost

Severe infection

Neutropenic bacterial, fungal, or viral illness may require ICU and costly treatment.

Confirm formulary and caps.

GVHD

Allogeneic recipients can develop acute or chronic organ involvement.

Plan rapid specialist access.

Graft failure or relapse

May require growth factors, donor boost, second transplant, or other therapy.

Not a routine inclusion.

Organ toxicity

Lung, liver, kidney, heart, neurologic, or mucosal injury can extend care.

Match ICU depth to risk.

Donor unavailable

Illness, collection failure, registry delay, or logistics can postpone conditioning.

Ask for backup-donor and refund rules.

Destination comparison

Compare India, Turkey, and Thailand for this procedure

The most suitable destination depends on the individual case, required team, treatment availability, travel route, legal eligibility, budget, and continuity after returning home.

Procedure planning comparison across India, Turkey, and Thailand
Decision factor	India	Turkey	Thailand	How to use this
Program breadth	Many large adult and pediatric HSCT programs.	Strong tertiary and academic programs with selected JACIE-certified activity.	Fewer programs, concentrated in Bangkok.	Match disease, donor, and age group.
Donor procurement	Related and registry pathways vary by center.	European registry geography may help selected searches but fees vary.	International procurement can add logistics and time.	Compare donor-stage scope separately.
Long stay	Accommodation can be lower-cost across cities.	Convenient for Europe and nearby regions but major-city housing adds cost.	Private support is mature with potentially higher living cost.	Model caregiver and 100-day access.

Decision guidance

When Turkey may fit and when to keep comparing

Turkey may fit when

A program experienced in the exact disease and donor type reviews complete records and provides a donor, admission, complication, and early-follow-up budget.

Keep comparing when

The quote uses one BMT price, excludes donor procurement without estimate, promises a universal success rate, or lacks clear ICU and infection support.

Stabilize first when

There is uncontrolled infection, bleeding, organ failure, or urgent leukemia progression that requires immediate local treatment.

Reports for review

Prepare a case file before requesting estimates

Submit original pathology and marrow data, molecular and cytogenetic results, complete treatment chronology and response, infection history, organ testing, HLA reports, donor relationship and health information, transfusion history, medicines, and home hematologist contact.

Upload medical reports

Disease file

Pathology and marrow slides or reports

Provide the complete pathology and marrow slides or reports as a readable record for clinical and cost review.

Flow, molecular, cytogenetic results

Provide the complete flow, molecular, cytogenetic results as a readable record for clinical and cost review.

Imaging and response assessments

Provide the complete imaging and response assessments as a readable record for clinical and cost review.

Complete treatment and toxicity chronology

Provide the complete complete treatment and toxicity chronology as a readable record for clinical and cost review.

Recipient safety

Heart, lung, kidney, liver tests

Provide the complete heart, lung, kidney, liver tests as a readable record for clinical and cost review.

Infection cultures and serology

Provide the complete infection cultures and serology as a readable record for clinical and cost review.

Transfusion and antibody history

Provide the complete transfusion and antibody history as a readable record for clinical and cost review.

Medicines, allergies, performance status

Provide the complete medicines, allergies, performance status as a readable record for clinical and cost review.

Donor and logistics

HLA typing for patient and donors

Provide the complete hla typing for patient and donors as a readable record for clinical and cost review.

Donor age, relationship, health and consent

Provide the complete donor age, relationship, health and consent as a readable record for clinical and cost review.

Registry search information

Provide the complete registry search information as a readable record for clinical and cost review.

Caregiver, housing, passport and travel plan

Provide the complete caregiver, housing, passport and travel plan as a readable record for clinical and cost review.

Common questions

Questions about cost, travel, and follow-up

Is BMT the same as stem cell transplant?

The terms overlap, but cells may come from marrow, peripheral blood, or cord; the source and donor pathway should be named.

Why is allogeneic transplant more expensive?

Donor work, GVHD prevention, immunosuppression, infection risk, monitoring, and longer recovery add complexity.

Is donor search included?

Often not fully. Ask about typing, registry, collection, courier, and cancellation charges.

How long must I remain in Turkey?

It varies widely; allogeneic care commonly requires prolonged nearby access through early immune recovery.

Can the donor travel later?

Timing depends on confirmatory testing, independent clearance, collection method, and backup planning. Do not book until the program confirms.

Does the package cover infection?

Usually only routine prevention. High-cost antimicrobial treatment, ICU, and extended admission may be additional.

What is engraftment?

It is recovery of blood-cell production from infused stem cells; timing and function are monitored closely.

Could I need another transplant?

Graft failure or relapse can lead to boost, second transplant, or other therapy, none of which should be assumed included.

When can I fly?

Only after the transplant team considers blood counts, infection, medicines, organ function, and emergency access acceptable.

What care continues at home?

Frequent hematology, drug levels, infection tests, disease monitoring, vaccines, late-effect screening, and urgent assessment continue.

Review and sources

How this guide was prepared

The range separates autologous, related allogeneic, and unrelated or complex pathways and explicitly recognizes donor procurement, conditioning, protected admission, early outpatient care, and complications. Current quality and regulatory sources informed the selection checks; the conversion is anchored near 17 July 2026. No public starting price was treated as a complete transplant budget.

This guide cannot confirm an HSCT indication, donor, conditioning regimen, infection safety, prognosis, or travel fitness. A transplant hematologist and authorized program must review the case and issue a staged estimate. Fever, bleeding, breathing difficulty, confusion, severe weakness, or rapid blood-cancer progression requires urgent local care.

Related planning